Oncolytics Biotech (TSE:ONC) has released an update.
Oncolytics Biotech Inc. is making significant strides in cancer treatment, with the FDA potentially accelerating approval of their breast cancer therapy, pelareorep. This development comes amid a global rise in cancer rates, with a 79% increase in new cases and a projected 77% increase by 2050. The company’s BRACELET-1 trial results are promising, setting the stage for a large study targeting HR+/HER2- metastatic breast cancer patients.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.
